诚达药业：预计2025年全年净亏损1100万元—1800万元

Core Viewpoint - Chengda Pharmaceutical is forecasting a net loss attributable to shareholders of the listed company for the year 2025, estimated between 11 million to 18 million yuan, with a net loss excluding non-recurring gains and losses projected between 27.5 million to 34.5 million yuan [1] Group 1: Financial Performance - The company has implemented effective sales strategies and market development efforts, leading to a steady increase in operating revenue [1] - The expansion of fixed assets due to completed fundraising projects has resulted in increased depreciation and amortization expenses [1] - The wholly-owned subsidiary, Shanghai Jiuqian Cheng Biomedical Co., Ltd., is still in the research and development phase for innovative drugs and has not yet generated revenue [1] Group 2: Impairment and Non-Recurring Gains - The company conducted impairment tests on inventory and investment properties at the end of the reporting period, leading to the recognition of impairment provisions, which negatively impacted net profit [1] - Non-recurring gains and losses are expected to affect net profit by approximately 16.5 million yuan, primarily from government subsidies and cash management investment income [1] Group 3: Year-on-Year Comparison - Despite the forecasted losses, the company expects a reduction in the loss margin compared to the same period last year [1]